Phase 1b/2 SEASTAR trial: Safety, pharmacokinetics, and preliminary efficacy of the poly(ADP)-ribose polymerase (PARP) inhibitor rucaparib and angiogenesis inhibitor lucitanib in patients with advanced solid tumors.

被引：3
|
作者：
Dumbrava, Ecaterina Elena
Shapiro, Geoffrey
Bendell, Johanna C.
Yap, Timothy A.
Jeselsohn, Rinath
Lepley, Denise M.
Hurley, Sabrina
Lin, Kevin K.
Liao, Michelle
Habeck, Jenn
Enke, Aaron
Hamilton, Erika P.
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[2] Dana Farber Canc Inst, Boston, MA 02115 USA
[3] Tennessee Oncol, Sarah Cannon Res Inst, Nashville, TN USA
[4] Clovis Oncol Inc, Boulder, CO USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期
关键词：
D O I：
10.1200/JCO.2021.39.15_suppl.3102
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3102
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Human mass balance study and metabolite profiling of 14C-niraparib, a novel poly(ADP-Ribose) polymerase (PARP)-1 and PARP-2 inhibitor, in patients with advanced cancer
    Lotte van Andel
    Z. Zhang
    S. Lu
    V. Kansra
    S. Agarwal
    L. Hughes
    M. M. Tibben
    A. Gebretensae
    L. Lucas
    M. J. X. Hillebrand
    H. Rosing
    J. H. M. Schellens
    J. H. Beijnen
    Investigational New Drugs, 2017, 35 : 751 - 765
  • [42] A Phase 1B Study of the Anti-PD-1 Monoclonal Antibody, Tislelizumab, in Combination with the Parp Inhibitor, Pamiparib, in Advanced Solid Tumors
    Friedlander, M.
    Meniawy, T.
    Markman, B.
    Mileshkin, L. R.
    Harnett, P.
    Millward, M.
    Lundy, J.
    Freimund, A. E.
    Norris, C.
    Wu, J.
    Paton, V.
    Wang, L.
    Gao, B.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2018, 14 : 58 - 59
  • [43] Human mass balance study and metabolite profiling of 14C-niraparib, a novel poly(ADP-Ribose) polymerase (PARP)-1 and PARP-2 inhibitor, in patients with advanced cancer
    van Andel, Lotte
    Zhang, Z.
    Lu, S.
    Kansra, V.
    Agarwal, S.
    Hughes, L.
    Tibben, M. M.
    Gebretensae, A.
    Lucas, L.
    Hillebrand, M. J. X.
    Rosing, H.
    Schellens, J. H. M.
    Beijnen, J. H.
    INVESTIGATIONAL NEW DRUGS, 2017, 35 (06) : 751 - 765
  • [44] Phase I study to assess the safety, tolerability, pharmacokinetics/pharmacodynamics and preliminary efficacy of SC10914 in patients with advanced solid tumors.
    Gong, Jifang
    Tang, Jinhai
    Yin, Yongmei
    Ye, Dingwei
    Zhang, Jian
    Zheng, Hong
    Gao, Yunong
    Jang, Haoyuan
    Chen, Xiao
    Zhang, Zhe
    Shen, Lin
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [45] A phase 1b, open label, single institution trial of nintedanib in combination with bevacizumab in patients with advanced solid tumors.
    Madan, Ankit
    Jones, Benjamin Scott
    Paluri, Ravi Kumar
    Jerome, Mary
    Miley, Debi
    Robert, Francisco
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [46] Pharmacokinetics, Safety, and Preliminary Efficacy of Oral Trifluridine/Tipiracil in Chinese Patients with Solid Tumors: A Phase 1b, Open-Label Study
    Wang, Xicheng
    Zhou, Jianfeng
    Li, Yan
    Ge, Yuping
    Zhou, Yanping
    Bai, Chunmei
    Shen, Lin
    CLINICAL PHARMACOLOGY-ADVANCES AND APPLICATIONS, 2020, 12 : 21 - 33
  • [47] A phase 1/2 trial of ORIN1001, a first-in-class IRE1 inhibitor, in patients with advanced solid tumors.
    Gabrail, Nashat Y.
    Hamilton, Erika P.
    Elias, Anthony D.
    Rimawi, Mothaffar F.
    Li, Chao
    Corvez, Maria Margarita
    Li, Wei
    Feng, Ying
    Wei, Jiao
    Greene, Stephanie
    Patterson, John
    Zeng, Qingping
    Hui, Ai-Min
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [48] A phase I study of the tolerability, safety, pharmacokinetics and preliminary antitumor effects of KBP-5209, a novel pan-HER inhibitor, in patients with advanced solid tumors.
    Piha-Paul, Sarina Anne
    Sharma, Sunil
    Shih, Chengkon
    O'Neil, Bert H.
    Zhou, Qinghong
    Ding, Yuli
    Ou, Na
    Yu, Tingting
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [49] DNA repair protein expression and response of homologous recombination deficient ovarian cancer to the poly(ADP-ribose) polymerase (PARP) inhibitor rucaparib in the ARIEL2 Part 1 study
    Hendrickson, Andrea E. Wahner
    Lin, Kevin K.
    Visscher, Daniel W.
    Hurley, Rachel M.
    Raponi, Mitch
    Harding, Thomas C.
    Murphy, Linda M.
    Wagner, Jill M.
    Giordano, Heidi
    McNeish, Iain
    Swisher, Elizabeth M.
    Kaufmann, Scott
    CANCER RESEARCH, 2017, 77
  • [50] Safety and efficacy of itacitinib, a selective JAK1 inhibitor, in advanced hepatocellular cancer: Phase 1b trial (JAKAL)
    Troiani, Alessandro
    Martinez, Maria
    Ward, Caroline
    Benartzi, Charlotte Wilhelm
    Pinato, David J.
    Sharma, Rohini
    FUTURE ONCOLOGY, 2024, 20 (36) : 2839 - 2847
12345